{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:39:58Z","timestamp":1789000798677,"version":"build-2803163510"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Purpose: This study aimed to assess the efficacy and safety of berberine(BBR) plus 5-aminosalicylic acid (5-ASA) for treating ulcerative colitis (UC). Methods: A comprehensive search was conducted in electronic databases, including Medline\/PubMed, Sinomed, Embase, CNKI, Wanfang, and VIP, through January 2024 to identify all randomized controlled trials (RCTs) that administered BBR conjunction in standard therapy(5-ASA) for to support the treatment of UC. The data were synthesized using a meta-analysis approach with RevMan 5.4.1. The primary endpoint was the clinical efficacy rate. In contrast, the secondary endpoints included the Baron score, disease activity index (DAI) score, symptom relief latency, inflammatory markers, immunological indicators, and adverse events. Results: In this analysis, 10 RCTs comprising 952 patients with UC were examined. BBR considerably improved the clinical efficacy rate (RR = 1.22, 95% CI [1.15, 1.30], <jats:italic>P<\/jats:italic> &lt; 0.00001), attenuated the Baron score (SMD = -1.72, 95% CI [-2.30, -1.13], <jats:italic>P<\/jats:italic> &lt; 0.00001) and reduced the DAI score (SMD = -2.93, 95% CI [-4.42, -1.43], <jats:italic>P<\/jats:italic> &lt; 0.00001). Additionally, it ameliorated clinical symptoms (SMD = -2.74, 95% CI [-3.45, 2.02], <jats:italic>P<\/jats:italic> &lt; 0.00001), diminished inflammatory responses (SMD = -1.59, 95% CI [-2.14, 1.04], <jats:italic>P<\/jats:italic> &lt; 0.00001), and modulated immune reactions (SMD = 1.06,95% CI [0.24,1.87], <jats:italic>P<\/jats:italic> &lt;0.00001). Nonetheless, the impact of BBR on reducing adverse reactions was not statistically significant (RR = 0.75, 95% CI [0.42, 1.33], <jats:italic>P<\/jats:italic> &gt; 0.05). Conclusion: BBR demonstrates substantial efficacy in treating UC without causing severe adverse reactions and may serve as a viable complementary therapy. However, its clinical application warrants confirmation by additional high-quality, low-bias RCTs.<\/jats:p>","DOI":"10.1371\/journal.pone.0309144","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:14:42Z","timestamp":1725646482000},"page":"e0309144","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"given":"Jilei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0575-0054","authenticated-orcid":true,"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"issue":"10","key":"pone.0309144.ref001","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative Colitis in Adults: A Review[J]","volume":"330","author":"B Gros","year":"2023","journal-title":"JAMA"},{"issue":"10401","key":"pone.0309144.ref002","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis[J].","volume":"402","author":"C Le Berre","year":"2023","journal-title":"Lancet"},{"issue":"10114","key":"pone.0309144.ref003","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]","volume":"390","author":"C Ng S","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"pone.0309144.ref004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis[J]","volume":"158","author":"S Singh","year":"2020","journal-title":"Gastroenterology"},{"issue":"33\u201334","key":"pone.0309144.ref005","first-page":"564","article-title":"Ulcerative Colitis-Diagnostic and Therapeutic Algorithms[J].","volume":"117","author":"T Kucharzik","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"pone.0309144.ref006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis[J].","volume":"6","author":"T Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0309144.ref007","doi-asserted-by":"crossref","first-page":"855075","DOI":"10.3389\/fcimb.2022.855075","article-title":"Gut Microbiota: The Potential Key Target of TCM\u2019s Therapeutic Effect of Treating Different Diseases Using the Same Method-UC and T2DM as Examples[J].","volume":"12","author":"B Zhang","year":"2022","journal-title":"Front Cell Infect Microbiol,"},{"issue":"5","key":"pone.0309144.ref008","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","article-title":"What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?[J]","volume":"162","author":"N Krugliak C","year":"2022","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0309144.ref009","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1039\/D1BM01765A","article-title":"An oral pH-activated \"nano-bomb\" carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative colitis[J].","volume":"10","author":"M Yang","year":"2022","journal-title":"Biomater Sci,"},{"issue":"Pt B","key":"pone.0309144.ref010","doi-asserted-by":"crossref","first-page":"115919","DOI":"10.1016\/j.jep.2022.115919","article-title":"Gegen Qinlian decoction activates AhR\/IL-22 to repair intestinal barrier by modulating gut microbiota-related tryptophan metabolism in ulcerative colitis mice[J]","volume":"302","author":"X Wang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"pone.0309144.ref011","doi-asserted-by":"crossref","first-page":"937029","DOI":"10.3389\/fphar.2022.937029","article-title":"Pharmacological effects of berberine on models of ulcerative colitis: A meta-analysis and systematic review of animal studies[J].","volume":"13","author":"S Hu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0309144.ref012","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1158\/1940-6207.CAPR-19-0258","article-title":"A Phase I Trial of Berberine in Chinese with Ulcerative Colitis[J]","volume":"13","author":"L Xu","year":"2020","journal-title":"Cancer Prev Res"},{"issue":"2","key":"pone.0309144.ref013","first-page":"253","article-title":"PRISMA 2020 and PRISMA-S: common questions on tracking records and the flow diagram[J].","volume":"110","author":"L Rethlefsen M","year":"2022","journal-title":"J Med Libr Assoc"},{"issue":"05","key":"pone.0309144.ref014","first-page":"292","article-title":"Consensus opinions on the diagnosis and treatment of inflammatory bowel disease(2018,Bei jing)[J].","volume":"38","author":"J L Z R Wu Kaichun","year":"2018","journal-title":"Chinese Journal of Digestion"},{"issue":"2","key":"pone.0309144.ref015","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ptr.8087","article-title":"International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023)[J].","volume":"38","author":"S Zhang","year":"2024","journal-title":"Phytother Res"},{"issue":"02","key":"pone.0309144.ref016","first-page":"105","article-title":"Consensus opinions on the integrated diagnosis and treatment of ulcerative colitis in traditional Chinese medicine and Western medicine (2017)[J].","volume":"26","author":"J. Li Junxiang C","year":"2018","journal-title":"Chinese Journal of Integrated Traditional Chinese and Western Medicine in Gastroenterology"},{"issue":"5375","key":"pone.0309144.ref017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.1.5375.89","article-title":"VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS[J]","volume":"1","author":"JH BARON","year":"1964","journal-title":"Br Med J"},{"issue":"1","key":"pone.0309144.ref018","first-page":"CD11450","article-title":"Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis[J].","volume":"1","author":"N Mohammed V","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0309144.ref019","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing Severity of Disease in Patients with Ulcerative Colitis[J]","volume":"49","author":"S Pabla B","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"10080","key":"pone.0309144.ref020","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis[J].","volume":"389","author":"R Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"pone.0309144.ref021","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/ibd\/izz149","article-title":"Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer[J]","volume":"25","author":"D Yao","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"pone.0309144.ref022","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjx160","article-title":"Intestinal T Cell Profiling in Inflammatory Bowel Disease: Linking T Cell Subsets to Disease Activity and Disease Course[J].","volume":"12","author":"C Smids","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"7","key":"pone.0309144.ref023","doi-asserted-by":"crossref","first-page":"e13524","DOI":"10.1111\/eci.13524","article-title":"Empirical assessment of prediction intervals in Cochrane meta-analyses[J]","volume":"51","author":"F Al A","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"pone.0309144.ref024","first-page":"135","article-title":"The effects of berberine hydrochloride tablets as an adjuvant treatment for distal ulcerative colitis and their impact on serum inflammatory factor levels in patients[J].","volume":"14","author":"D Chen","year":"2020","journal-title":"Chin J Mod Drug Appl"},{"issue":"22","key":"pone.0309144.ref025","first-page":"46","article-title":"Effect of mesalazine combined with berberine on the levels of TNF -o.IL-17 and IL-23 in patients with distal ulcerative colitis[J].","volume":"59","author":"Y Chen","year":"2021","journal-title":"China Modern Doctor"},{"issue":"2","key":"pone.0309144.ref026","first-page":"55","article-title":"Berberine Hydrochloride Combined with Salazosulfapyridine in the Treatment of Ulcerative Colitis; A Clinical Study[J]","volume":"42","author":"H. Cheng","year":"2022","journal-title":"Chinese Journal of Colorectal and Anal Diseases"},{"issue":"1","key":"pone.0309144.ref027","first-page":"85","article-title":"Clinical study on Berberine Hydrochloride Tablets combined with sulfasalazine in treatment of ulcerative colitis[J].","volume":"36","author":"W Cui","year":"2021","journal-title":"Drugs & Clinic"},{"issue":"12","key":"pone.0309144.ref028","first-page":"949","article-title":"Effects of chlorhexidine hydrochloride on intestinal flora and immunestatus in patients with ulcerative colitis[J].","volume":"28","author":"J Gan","year":"2020","journal-title":"Chin J Integr Trad West Med Dig"},{"issue":"6","key":"pone.0309144.ref029","first-page":"771","article-title":"Salt of berberine combined with mesalazine for the treatment of ulcerative colitis: an observational study on the therapeutic effects[J].","volume":"27","author":"P. Wang","year":"2020","journal-title":"Clinical Medical Engineering"},{"issue":"23","key":"pone.0309144.ref030","first-page":"4371","article-title":"Evaluation of the therapeutic effects of berberine hydrochloride tablets combined with mesalazine in the treatment of patients with distal ulcerative colitis[J].","volume":"30","author":"Y Wang","year":"2021","journal-title":"HENAN MEDICAL RESEARCH"},{"issue":"7","key":"pone.0309144.ref031","first-page":"506","article-title":"The therapeutic efficacy of berberine combined with mesalazine and its impact on inflammatory factors in patients with distal ulcerative colitis[J]","volume":"28","author":"L. Wei","year":"2019","journal-title":"Proceeding of Clinical Medicine"},{"issue":"8","key":"pone.0309144.ref032","first-page":"541","article-title":"Effects of berberine combined with mesalazine on the treatment of distal ulcerative colitis and its impact on inflammatory factors in patients[J]","volume":"25","author":"Q Xu","year":"2020","journal-title":"Modern Digestion&lntervention"},{"issue":"12","key":"pone.0309144.ref033","first-page":"3183","article-title":"Clinical study on Berberine Hydrochloride Tablets combined with mesalazine intreatment of distal ulcerative colitis[J].","volume":"33","author":"T Zhu","year":"2018","journal-title":"Drugs & Clinic"},{"key":"pone.0309144.ref034","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fimmu.2020.00104","article-title":"The Imbalance of Circulating Follicular Helper T Cells and Follicular Regulatory T Cells Is Associated With Disease Activity in Patients With Ulcerative Colitis[J].","volume":"11","author":"Y Long","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0309144.ref035","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative Colitis[J].","volume":"94","author":"D Feuerstein J","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"pone.0309144.ref036","doi-asserted-by":"crossref","first-page":"1083788","DOI":"10.3389\/fimmu.2022.1083788","article-title":"Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy[J].","volume":"13","author":"C Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"pone.0309144.ref037","doi-asserted-by":"crossref","first-page":"111129","DOI":"10.1016\/j.biopha.2020.111129","article-title":"Berberine in the treatment of ulcerative colitis: A possible pathway through Tuft cells[J]","volume":"134","author":"X Xiong","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"pone.0309144.ref038","doi-asserted-by":"crossref","first-page":"e14176","DOI":"10.1016\/j.heliyon.2023.e14176","article-title":"Berberine promotes M2 macrophage polarisation through the IL-4-STAT6 signalling pathway in ulcerative colitis treatment[J].","volume":"9","author":"K Xiong","year":"2023","journal-title":"Heliyon"},{"key":"pone.0309144.ref039","doi-asserted-by":"crossref","first-page":"1352946","DOI":"10.3389\/fimmu.2024.1352946","article-title":"Macrophage polarization: an important role in inflammatory diseases[J].","volume":"15","author":"M Luo","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"pone.0309144.ref040","first-page":"e320722","article-title":"Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota[J]","volume":"10","author":"X Li","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"11","key":"pone.0309144.ref041","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","article-title":"Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing[J]","volume":"72","author":"F Neurath M","year":"2023","journal-title":"Gut"},{"issue":"4","key":"pone.0309144.ref042","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000509393","article-title":"A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis[J]","volume":"5","author":"H Radeke H","year":"2020","journal-title":"Inflamm Intest Dis"},{"issue":"3","key":"pone.0309144.ref043","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis[J]","volume":"21","author":"H Nakase","year":"2022","journal-title":"Autoimmun Rev"},{"key":"pone.0309144.ref044","first-page":"100114","article-title":"Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells[J]","volume":"X4","author":"N Salah","year":"2022","journal-title":"Int J Pharm"},{"issue":"1","key":"pone.0309144.ref045","article-title":"Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and In Vivo Effects[J].","volume":"13","author":"F Laurindo L","year":"2023","journal-title":"Metabolites"},{"key":"pone.0309144.ref046","doi-asserted-by":"crossref","first-page":"116330","DOI":"10.1016\/j.jep.2023.116330","article-title":"Clinopodium chinense Kuntze ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by reducing systematic inflammation and regulating metabolism[J]","volume":"309","author":"Y Wang","year":"2023","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"pone.0309144.ref047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease[J].","volume":"8","author":"L Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"pone.0309144.ref048","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032696","article-title":"CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease[J].","volume":"24","author":"R Gomez-Bris","year":"2023","journal-title":"Int J Mol Sci"},{"key":"pone.0309144.ref049","doi-asserted-by":"crossref","first-page":"105040","DOI":"10.1016\/j.phrs.2020.105040","article-title":"Targeting T cells in inflammatory bowel disease[J]","volume":"159","author":"P Giuffrida","year":"2020","journal-title":"Pharmacol Res"},{"issue":"8","key":"pone.0309144.ref050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.it.2020.06.008","article-title":"Rewriting History: Epigenetic Reprogramming of CD8(+) T Cell Differentiation to Enhance Immunotherapy[J].","volume":"41","author":"C Zebley C","year":"2020","journal-title":"Trends Immunol"},{"key":"pone.0309144.ref051","doi-asserted-by":"crossref","first-page":"864748","DOI":"10.3389\/fimmu.2022.864748","article-title":"Cytolytic CD4(+) and CD8(+) Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease[J].","volume":"13","author":"S Bolivar-Wagers","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"pone.0309144.ref052","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of Inflammatory Bowel Disease: Innate Immune System[J].","volume":"24","author":"A Saez","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"17","key":"pone.0309144.ref053","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.7150\/thno.62046","article-title":"Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota[J].","volume":"11","author":"L Tong","year":"2021","journal-title":"Theranostics"},{"key":"pone.0309144.ref054","doi-asserted-by":"crossref","first-page":"109108","DOI":"10.1016\/j.intimp.2022.109108","article-title":"Astragalus polysaccharide alleviates ulcerative colitis by regulating the balance of Tfh\/Treg cells[J]","volume":"111","author":"Y Zhong","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"pone.0309144.ref055","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ibd\/izad258","article-title":"Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn\u2019s Disease[J]","volume":"30","author":"N Tubau-Juni","year":"2024","journal-title":"Inflamm Bowel Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:15:17Z","timestamp":1725646517000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309144"}},"subtitle":[],"editor":[{"given":"Nicholas A.","family":"Pullen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309144","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}